|
|
|
|
Stockhead "90 Seconds With" interview
Anatara Lifesciences LTd (ASX:ANR) CEO Steven Lydeamore was recently interviewed by Stockhead, for its "90 Seconds With" interview series. Steve provided an overview of the Company's key milestones for the next 12 months.
To watch the video interview, please click on the link below:
https://stockhead.com.au/stockhead-tv/video-90-seconds-with-steven-lydeamore-anatara-lifesciences/
|
|
Message from the CEO
During the last 12 months, Anatara has made significant steps in its path to commercialise our innovative Gastrointestinal ReProgramming (GaRP) dietary supplement. 2020 marks the start of an exciting year as we prepare to commence our clinical trial in irritable bowel syndrome (IBS) and we remain firmly on track to announce an anticipated partnering deal by the end of the year.
In January, we released a summary of our preclinical program, providing strong scientific proof that our GaRP dietary supplement may be the breakthrough product so desperately needed by patients suffering chronic bowel conditions. Our GaRP dietary supplement has been shown to:
* Address the dysbiosis of the microbiome;
* Reduce gut inflammation;
* Promote mucosal healing;
* And importantly, does not affect the uptake or potential activity of probiotics.
Furthermore, GaRP has the potential to provide:
* An adjuvant effect in reducing inflammation with the co-administration of disease-modifying medications;
* Dose reduction of disease-modifying medications known to have devastating side-effects.
We remain highly encouraged by these results, providing Anatara with every confidence going into partnering discussions later this year, where I look forward to putting my many years of successful business development experience to work.
In parallel, Anatara continues to explore options to build marketing capability and a pipeline of over-the-counter (OTC) gastrointestinal (GI) products in Australia with negotiations advanced with two potential product partners.
Pivoting to our animal health business, Anatara remains confident that a substantial market opportunity for Detach® exists, with more pressure than ever on producers to reduce their antibiotic use and find suitable alternatives which minimise illnesses, such as scour, on farms. We have advanced discussions with a number of potential international licensees for Detach® underway and are confident of a positive announcement by the end of the year.
I would like to again thank shareholders for their continued patience and support as we continue to execute on the strategic re-partnering of Detach® and the further clinical development of our breakthrough GaRP dietary supplement, which we believe will deliver much-needed relief for IBS and IBD patients and drive value for our shareholders.
I look forward to keeping you updated on our progress in the coming months.
Steven Lydeamore
Chief Executive Officer
slydeamore@anatara.com
|
|
Anatara in the news
Anatara received strong media coverage over the last few months on the back of recent announcements regarding the latest results from our GaRP preclinical program, finalisation of the GaRP clinical trial protocol and the Company's plans to build marketing capabilities and a pipeline of over-the-counter gastrointestinal health products in Australia. Highlights of recent stories include:
TechInvest Magazine Online - Anatara takes next step in testing its answer to US$8 billion global IBS issue
Health News Office - Digestive Health Supplements Market Segmentation Detailed Study with Forecast to 2028
ABN Newswire - CEO Interview with Steve Lydeamore
Biospace - "Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook"
|
|
A spotlight on...
As we complete the preclinical program for our GaRP dietary supplement, we thought it timely to introduce a key Anatara team member and the smiley face behind our GaRP in vitro preclinical studies - Kylie Wilkie, Clinical Trials Manager.
Kylie joined Anatara in 2015 to facilitate the implementation and management of Anatara’s Detach® clinical trial program. Kylie has over 19 years working in the veterinary and biotechnology industries. Of these, six years were as a small animal veterinary nurse and almost 10 years as a Senior Clinical Research Associate for Zoetis (formally Pfizer Animal Health), the world’s largest animal health company. Following the licencing of Detach® in 2018, Kylie commenced working on Anatara’s human product pipeline. Kylie was instrumental in the successful completion of our GaRP in vitro studies and is presently engaged in setting up the human clinical study for GaRP in IBS.
Kylies holds a Certificate IV in Veterinary Nursing, an Advanced Diploma of Business from Swinburne University of Technology and is currently studying for a Bachelor of Biological Sciences at La Trobe University.
A mother of two, Kylie loves spending time with her fun-loving children, going on holidays and swimming with sharks (true story!).
We look forward to bringing you more profiles of our key people over the coming months.
|
|
Connect with us today!
Keep up to date with what's happening at Anatara Lifesciences and the latest industry news and events.
Our Investor Centre has information on ANR reports, presentations, announcements, events and other disclosures.
|
|
|
|
|
|
|
|
|
